Hydrogen Cyanide Poisoning 

  • Author: Lewis S Nelson, MD, FACEP, FAACT, FACMT; Chief Editor: Robert G Darling, MD, FACEP   more...
 
Updated: Dec 9, 2011
 

Background

This article addresses the management of hydrogen cyanide (HCN) poisoning. HCN (North Atlantic Treaty Organization [NATO] designation AC) is 1 of 2 cyanide chemical warfare agents[1, 2, 3] ; the other is cyanogen chloride (NATO designation CK).

Cyanide is a rapidly lethal agent when used in enclosed spaces where high concentrations can be achieved easily.[4, 5, 6, 7] In addition, because of the extensive use of cyanide in industry in the United States, this agent presents a credible threat for terrorist use.[2] Emergency physicians may also encounter cyanide casualties resulting from industrial accidents or fires.

Cyanide was first used as a chemical weapon in the form of gaseous HCN in World War I. Starting in 1915, the French military used approximately 4000 tons of cyanide, without notable success. The failure of this measure was probably attributable to the high volatility of cyanide and the inability of the 1- to 2-lb munitions used to deliver the amounts of chemical required for biologic effects.[2, 3]

The introduction of cyanogen chloride by the French in 1916 made available a compound that, being both more toxic and less volatile, was a more effective chemical agent. Other alleged military uses of cyanide include Japanese attacks on China before and during World War II and Iraqi attacks on Kurds in the 1980s.

For related information, see the Disaster Preparedness and Aftermath Resource Center.[8, 9]

Next

Pathophysiology

Whereas liquid cyanide can be absorbed through the skin or eyes, the primary route of exposure is by inhalation or ingestion. Once absorbed, cyanide is distributed rapidly to all organs and tissues in the body. It inhibits multiple enzymes, most importantly cytochrome a3, a component of cytochrome oxidase in the electron transport chain of the mitochondria. This prevents intracellular oxygen use and the generation of cellular adenosine triphosphate (ATP), causing aerobic energy production to cease.

Hydrogen ions accumulate as they fail to combine with oxygen at the end of the electron transport chain, causing a metabolic acidosis. As anaerobic metabolism ensues, pyruvate accumulates and is converted to lactate, resulting in an elevated lactate concentration.[10]

The LCt50 (the concentration-time product capable of killing 50% of the exposed group) for HCN is 2500-5000 mg/min/m3. The lethal oral doses of HCN and cyanide salts are estimated to be 50 mg and 100-200 mg, respectively. The LD50 (the dose capable of killing 50% of the exposed group) for skin exposures is estimated to be 100 mg/kg. Vapor exposures in high concentrations (at or above the LCt50) typically can cause death in 6-8 minutes.[11]

Previous
Next

Etiology

Causes of cyanide casualties include deliberate use as a chemical warfare agent, industrial exposures, and toxic byproducts of fires.[12, 11] Emergency physicians are unlikely to encounter casualties from HCN used as a weapon except in the setting of a terrorist attack[11] ; the other causes are more common.

Specific industrial processes involving cyanide include metal cleaning, reclaiming, or hardening; fumigation; electroplating; and photo processing.[12] Other potential sources of cyanide are fires involving plastics or synthetics, acrylic nail removers containing acetonitrile or propionitrile, and nitroprusside infusions.[12] Numerous plants (eg, apricots, apples, and bitter almonds) contain within their seeds and pits amygdalin, which can be hydrolyzed to HCN after the ingestion and may be poisonous in large quantities.[12]

Previous
Next

Prognosis

The prognosis is good for patients who have only minor symptoms that do not necessitate the administration of antidotes.

The prognosis is poor in patients with cyanide poisoning sufficiently severe to cause cardiovascular collapse. In a mass casualty setting, these victims would be classified as expectant.

The prognosis is fair for patients with seizures or recent-onset apnea if antidotes can be administered rapidly. In a mass casualty setting, these victims would be classified as immediate.

Previous
Next

Patient Education

It is important that patients exposed to HCN be educated about potential neurologic sequelae and the importance of follow-up evaluation.

For patient education resources, see the Bioterrorism and Warfare Center and the Poisoning Center, as well as Chemical Warfare, Personal Protective Equipment, Cyanide Poisoning, and Carbon Monoxide Poisoning.

Previous
 
 
Contributor Information and Disclosures
Author

Lewis S Nelson, MD, FACEP, FAACT, FACMT  Associate Professor, Department of Emergency Medicine, New York University School of Medicine; Attending Physician, Department of Emergency Medicine, Bellevue Hospital Center, New York University Medical Center and New York Harbor Healthcare System

Lewis S Nelson, MD, FACEP, FAACT, FACMT is a member of the following medical societies: American Academy of Clinical Toxicology, American College of Emergency Physicians, American College of Medical Toxicology, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Coauthor(s)

Colleen M Rivers, MD  Senior Fellow in Medical Toxicology, New York City Poison Control Center, Bellevue Hospital Center

Disclosure: Nothing to disclose.

Erik D Schraga, MD  Staff Physician, Department of Emergency Medicine, Mills-Peninsula Emergency Medical Associates

Disclosure: Nothing to disclose.

Andre Pennardt, MD, FACEP, FAAEM, FAWM  Clinical Associate Professor of Emergency Medicine, Medical College of Georgia; Assistant Professor of Military and Emergency Medicine, Uniformed Services University of the Health Sciences; Consulting Staff, Departments of Emergency Medicine, Aviation Medicine and Dive Medicine, Womack Army Medical Center

Andre Pennardt, MD, FACEP, FAAEM, FAWM is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, Association of Military Surgeons of the US, International Society for Mountain Medicine, National Association of EMS Physicians, Special Operations Medical Association, and Wilderness Medical Society

Disclosure: Nothing to disclose.

Chief Editor

Robert G Darling, MD, FACEP  Adjunct Clinical Assistant Professor of Military and Emergency Medicine, Uniformed Services University of the Health Sciences, F Edward Hebert School of Medicine; Associate Director, Center for Disaster and Humanitarian Assistance Medicine

Robert G Darling, MD, FACEP is a member of the following medical societies: American College of Emergency Physicians, American Medical Association, American Telemedicine Association, and Association of Military Surgeons of the US

Disclosure: Nothing to disclose.

Additional Contributors

Rick Kulkarni, MD Attending Physician, Department of Emergency Medicine, Cambridge Health Alliance, Division of Emergency Medicine, Harvard Medical School

Rick Kulkarni, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine

Disclosure: WebMD Salary Employment

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Suzanne White, MD Medical Director, Regional Poison Control Center at Children's Hospital, Program Director of Medical Toxicology, Associate Professor, Departments of Emergency Medicine and Pediatrics, Wayne State University School of Medicine

Suzanne White, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Clinical Toxicology, American College of Epidemiology, American College of Medical Toxicology, American Medical Association, and Michigan State Medical Society

Disclosure: Nothing to disclose.

References
  1. Armstrong J. Chemical warfare. RN. Apr 2002;65(4):32-9. [Medline].

  2. Greenfield RA, Brown BR, Hutchins JB. Microbiological, biological, and chemical weapons of warfare and terrorism. Am J Med Sci. Jun 2002;323(6):326-40. [Medline].

  3. Rosenbloom M, Leikin JB, Vogel SN. Biological and chemical agents: a brief synopsis. Am J Ther. Jan-Feb 2002;9(1):5-14. [Medline].

  4. Baskin SI, Brewer TG. Cyanide poisoning. In: Medical Aspects of Chemical and Biological Warfare. 1997:271-286.

  5. Morocco AP. Cyanides. Crit Care Clin. Oct 2005;21(4):691-705, vi. [Medline].

  6. Sidell FR, Patrick WC, Dashiell TR. Cyanide. In: Jane's Chem-Bio Handbook. 1998:79-88.

  7. USACHPPM. Cyanide. In: USACHPPM Tech Guide 244: The Medical NBC Battlebook. 1999:V-36-37.

  8. Burda AM, Sigg T. Pharmacy preparedness for incidents involving weapons of mass destruction. Am J Health Syst Pharm. Dec 1 2001;58(23):2274-84. [Medline].

  9. Lynch EL, Thomas TL. Pediatric considerations in chemical exposures: are we prepared?. Pediatr Emerg Care. Mar 2004;20(3):198-208. [Medline].

  10. Baud FJ, Borron SW, Megarbane B. Value of lactic acidosis in the assessment of the severity of acute cyanide poisoning. Crit Care Med. Sep 2002;30(9):2044-50. [Medline].

  11. Musshoff F, Schmidt P, Daldrup T. Cyanide fatalities: case studies of four suicides and one homicide. Am J Forensic Med Pathol. Dec 2002;23(4):315-20. [Medline].

  12. Brennan RJ, Waeckerle JF, Sharp TW. Chemical warfare agents: emergency medical and emergency public health issues. Ann Emerg Med. Aug 1999;34(2):191-204. [Medline].

  13. Department of the Army. Blood agents (Cyanogens). In: Field Manual 8-285: Treatment of Chemical Agent Casualties and Conventional Military Chemical Injuries. 1995:VI-1-2.

  14. USAMRICD. Cyanide. In: Field Management of Chemical Casualties Handbook. 1996:37-40.

  15. USAMRICD. Cyanide. In: Medical Management of Chemical Casualties Handbook. 1999:38-58.

  16. Kirk MA, Gerace R, Kulig KW. Cyanide and methemoglobin kinetics in smoke inhalation victims treated with the cyanide antidote kit. Ann Emerg Med. Sep 1993;22(9):1413-8. [Medline].

  17. Borron SW, Baud FJ, Mégarbane B, Bismuth C. Hydroxocobalamin for severe acute cyanide poisoning by ingestion or inhalation. Am J Emerg Med. Jun 2007;25(5):551-8. [Medline].

  18. Martin CO, Adams HP. Neurological aspects of biological and chemical terrorism: a review for neurologists. Arch Neurol. Jan 2003;60(1):21-5. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.